Want to see KR:000020 full AI Analyst Report?
Top Page
Dong Wha Pharm Co., Ltd.
(000020)
Select Model
Select Model
Rating:58Neutral
Price Target:
₩5,408.00
Action:N/A
Date:10/28/26
The score is driven primarily by mid-level financial performance: the balance sheet is fairly healthy, but thin/volatile profitability and especially negative free cash flow with weak cash conversion weigh on quality and consistency. Valuation is a clear positive with a low P/E and high dividend yield. Technicals are mixed, with the stock below key short- and long-term moving averages and subdued momentum indicators.
Positive Factors
Balance Sheet
Moderate leverage and steadily growing equity provide a relatively sound financial foundation for the pharmaceutical business. This balance-sheet resilience can support ongoing operations and product investment while reducing vulnerability to earnings weakness compared with a highly leveraged structure.
Negative Factors
Free Cash Flow
Negative free cash flow means operating cash generation has not yet covered the company’s cash investment and other outflows. Until this improves, internally generated funds may be insufficient to support growth consistently, limiting financial flexibility and weakening the quality of reported earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet
Moderate leverage and steadily growing equity provide a relatively sound financial foundation for the pharmaceutical business. This balance-sheet resilience can support ongoing operations and product investment while reducing vulnerability to earnings weakness compared with a highly leveraged structure.
Read all positive factors
Dong Wha Pharm Co., Ltd. (000020) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩144.41B
Dividend Yield4.7%
Average Volume (3M)381.85K
Price to Earnings (P/E)7.9
Beta (1Y)>-0.01
Revenue Growth6.59%
EPS Growth185.66%
CountryKR
Employees838
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)652.59
Shares Outstanding27,931,470
10 Day Avg. Volume190,463
30 Day Avg. Volume381,849
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)0.46
Price to Sales (P/S)0.35
P/FCF Ratio-4.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Dong Wha Pharm Co., Ltd. Business Overview & Revenue Model
Company Description
Dongwha Pharm Co., Ltd. is a South Korean entity primarily engaged in the production and distribution of pharmaceutical goods. The company's diverse offerings include prescription-only medications addressing a wide spectrum of health concerns such...
Dong Wha Pharm Co., Ltd. Financial Statement Overview
Summary
Income Statement
55
Neutral
Balance Sheet
74
Positive
Cash Flow
42
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 513.24B | 496.39B | 464.87B | 361.11B | 340.43B | 293.02B |
| Gross Profit | 214.76B | 203.33B | 214.26B | 190.42B | 180.99B | 149.35B |
| EBITDA | 41.65B | 21.16B | 28.72B | 48.74B | 38.23B | 39.41B |
| Net Income | 18.08B | 8.69B | 5.56B | 27.44B | 20.38B | 17.87B |
Balance Sheet | ||||||
| Total Assets | 653.67B | 642.17B | 619.63B | 564.97B | 461.14B | 447.80B |
| Cash, Cash Equivalents and Short-Term Investments | 32.45B | 24.34B | 43.50B | 88.83B | 107.69B | 121.51B |
| Total Debt | 123.64B | 118.41B | 96.99B | 47.10B | 6.66B | 11.47B |
| Total Liabilities | 238.03B | 240.55B | 217.96B | 157.92B | 82.46B | 87.67B |
| Stockholders Equity | 394.87B | 379.53B | 373.37B | 371.78B | 364.40B | 346.93B |
Cash Flow | ||||||
| Free Cash Flow | -3.28B | -37.48B | -78.07B | 2.82B | 9.13B | 11.26B |
| Operating Cash Flow | 27.37B | 15.70B | -4.00B | 29.17B | 29.22B | 36.03B |
| Investing Cash Flow | -26.17B | -41.18B | -74.79B | 2.86B | -43.27B | -25.41B |
| Financing Cash Flow | 3.63B | 13.40B | 31.36B | 5.87B | -12.01B | -8.78B |
Dong Wha Pharm Co., Ltd. Technical Analysis
Negative
―
Price Trends
5211.00
Negative
5157.80
Positive
5574.01
Negative
Market Momentum
17.59
Positive
47.15
Neutral
12.50
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:000020, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 5312.00, equal to the 50-day MA of 5211.00, and equal to the 200-day MA of 5574.01, indicating a bearish trend. The MACD of 17.59 indicates Positive momentum. The RSI at 47.15 is Neutral, neither overbought nor oversold. The STOCH value of 12.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:000020.
Dong Wha Pharm Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | ₩141.34B | 8.31 | ― | 3.18% | 7.46% | -14.42% | |
58 Neutral | ₩144.41B | 7.86 | ― | 4.70% | 6.59% | 185.66% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | ₩128.67B | 7.32 | ― | 0.30% | -17.85% | 81.91% | |
49 Neutral | ₩123.84B | 24.66 | ― | 0.97% | 14.83% | 1148.11% | |
47 Neutral | ₩167.66B | -4.41 | ― | 0.96% | -4.54% | -88.02% | |
44 Neutral | ₩117.74B | -0.85 | ― | ― | -2.43% | -234.71% |
* General Sector Average
KR:000020
Dong Wha Pharm Co., Ltd.
5,210.00
-990.45
-15.97%
KR:000520
Samil Pharmaceutical Co., Ltd.
7,780.00
-1,690.00
-17.85%
KR:001360
SAMSUNG PHARMACEUTICAL.CO.,Ltd.
1,251.00
-242.00
-16.21%
KR:214390
Kyongbo Pharmaceutical Co., Ltd.
5,180.00
-639.40
-10.99%
KR:271980
Jeil Pharmaceutical Co. Ltd.
8,830.00
-5,760.00
-39.48%
KR:293480
Hana Pharm Co., Ltd.
8,170.00
-3,311.32
-28.84%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.